Considering the fact that PSMA PET/CT is now suggested as a suitable replacement for conventional imaging by providing superior accuracy for staging patients with high-risk prostate cancer before curative-intent treatment [7], we believe similar questions regarding its ability in this clinical setting should be noted. The gene discussed is FOLH1; the disease is Familial prostate cancer.